Augustine Asset Management 投资了 Royalty Pharma，该公司的收益超出预期并预计会强劲增长。 Augustine Asset Management invested in Royalty Pharma, which beat earnings forecasts and projects strong growth.

Augustine资产管理公司投资200 000美元投资皇家医药PLC(NASDAQ:RPRX),在第一季度购买6 439股股份。 Augustine Asset Management Inc. invested $200,000 in Royalty Pharma PLC (NASDAQ:RPRX), buying 6,439 shares in the first quarter. 皇家药房报告,每股收入为1.06美元,比分析师预测的多7美元,收入为8.39亿美元。 Royalty Pharma reported earnings per share of $1.06, exceeding analyst forecasts by $0.07, and had a revenue of $839 million. 分析员预测,本年度该公司将按每股4.49美元的收入计算。 Analysts predict the company will post 4.49 earnings per share for the current year. 皇家药房在生物制药业运作,重点是获得特许权使用费和筹资创新。 Royalty Pharma operates in the biopharmaceutical industry, focusing on acquiring royalties and funding innovations.